Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

Giving good guidance and meeting stated timelines gives a company credibility with institutional investors. Credibility is something Missling sorely lacks. Even with a Nasdaq listing, Anavex still acts like and is viewed as an OTCBB company. As to the impact of an FDA approval for Trofinetide for Rett, I expect ACAD will move significantly higher because the stock will have been dramatically de-risked and because the approval of the first drug for a terrible childhood disease will generate global media interest and coverage. You can bet Rettsyndrome.org and other Rett advocacy groups will be pushing the story hard to healthcare reporters globally and so will Acadia. You’ll see.